Boz İbrahim Bekir, Aytürk Salt Semra, Salt Ömer, Sayın Niyazi Cenk, Dibirdik İlker
Department of Internal Disease, Akdeniz University, Antalya, Turkey.
Department of Endocrinology and Metabolic Diseases, Kayseri City Hospital, Kayseri, Turkey.
Diabetes Metab Syndr Obes. 2023 Aug 23;16:2515-2521. doi: 10.2147/DMSO.S424651. eCollection 2023.
This study sought to investigate whether asprosin can be used in the diagnosis of GDM or for diagnostic purposes in high-risk pregnancies, along with a review of other parameters that may be associated with serum asprosin levels.
The study investigated the association between gestational diabetes mellitus (GDM) and asprosin levels. A total of 93 participants; 30 patients with GDM, 33 healthy pregnant women with normal glucose tolerance (NGT), and 30 healthy non-diabetic women (control group) at the Endocrinology and Metabolic Diseases outpatient clinic of a tertiary care university hospital were enrolled in the study. Patients with GDM and NGT were examined in terms of GDM between the 24th and 28th week of pregnancy (2nd trimester). Patient data were collected during routine examinations, and asprosin levels were measured using the ELISA method. All participants underwent testing for measurements of serum hemoglobin, insulin, C-peptide, fasting plasma glucose, and glycated hemoglobin (HbA1c) levels following a fasting period of at least eight hours.
Asprosin levels were higher in pregnant women with NGT and with GDM versus controls (Control-NGT asprosin, = 0.001; Control-GDM asprosin, = 0.001). Pregnant women with GDM had higher asprosin levels than those with NGT ( = 0.001). In detecting GDM in pregnant women, an asprosin cutoff value of >31.709 ng/mL yielded a sensitivity of 93.3%, specificity of 90.9%, positive predictive value of 90.3%, and negative predictive value of 93.75% (p < 0.001).
Serum asprosin levels can potentially be used as a marker in the diagnosis of GDM.
本研究旨在探讨阿朴脂蛋白是否可用于妊娠期糖尿病（GDM）的诊断或高危妊娠的诊断，同时回顾其他可能与血清阿朴脂蛋白水平相关的参数。
本研究调查了妊娠期糖尿病（GDM）与阿朴脂蛋白水平之间的关联。在一所三级医疗大学医院的内分泌与代谢疾病门诊，共纳入93名参与者，其中30例GDM患者、33例糖耐量正常（NGT）的健康孕妇以及30例健康非糖尿病女性（对照组）。GDM患者和NGT患者在妊娠第24至28周（孕中期）接受GDM相关检查。在常规检查期间收集患者数据，并采用酶联免疫吸附测定（ELISA）法测量阿朴脂蛋白水平。所有参与者在至少禁食8小时后接受血清血红蛋白、胰岛素、C肽、空腹血糖和糖化血红蛋白（HbA1c）水平的检测。
NGT孕妇和GDM孕妇的阿朴脂蛋白水平高于对照组（对照组-NGT阿朴脂蛋白， = 0.001；对照组-GDM阿朴脂蛋白， = 0.001）。GDM孕妇的阿朴脂蛋白水平高于NGT孕妇（ = 0.001）。在检测孕妇GDM时，阿朴脂蛋白临界值>31.709 ng/mL时，灵敏度为93.3%，特异度为90.9%，阳性预测值为90.3%，阴性预测值为93.75%（p < 0.001）。
血清阿朴脂蛋白水平有可能作为GDM诊断的标志物。
